Is it possible to test for circulating tumour cells in a tissue sample?
We calculate the number of circulating tumour cells from the total amount of blood cells, expressed as the volume of circulating tumour cells per millilitre of blood. This cannot be calculated from a tissue sample. To conduct a circulating tumour cell test a blood sample must be provided.
An exception is brain tumours, as these cancer cells cannot be detected in the blood.
Can the circulating tumour cell test be done during chemotherapy treatment?
A patient has to wait seven days after chemotherapy treatment before taking the RGCC circulating tumour cell test.
Do you perform the test on circulating tumour cells (CTCs) from blood samples?
The main cells of interest in our analytic platform are CTCs, which are obtained by negative selection and sorting via flow cytometry. You can find further information here [link to site].
Can patients with lymphoma or leukemia have their circulating tumour cell (CTC count measured?
Yes. Patients with lymphoma or leukemia can use an RGCC test to measure their circulating tumour cell count.
Do circulating tumour cells (CTCs) predict the site of relapse and metastases?
Our Metastat test provides this information over a period of three years. It compares profiles of CTCs and metastases to detect relevant markers at the site of relapse.
Why is the circulating tumour cell (CTC) count not indicated in tissue samples?
The tissue sample taken from the tumour during a biopsy is part of the tumour contain cancerous cells, so there is no need to search for CTC populations.
Is it possible to determine from a blood test whether a person will respond to a specific chemotherapeutic agent?
Testing for circulating tumour cells (CTCs) can reveal sensitivity and resistance to several factors. Applying this requires the cooperation and expertise of an oncologist who specialises in pharmacology to schedule dosages, timing and cycles for a patient.
Which is the most comprehensive test?
The Onconomics Plus test provides information about the sensitivity or resistance of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient.
The ChemoSNiP test can be used to predict whether a patient will respond to drugs and metabolise them properly.
Can I include additional substances for testing?
We can include additional natural substances in the Onconomics Plus or Onconomics Extracts tests. Additional chemotherapy drugs can be included in the Onconomics test.
How often do you suggest patients do a follow up test?
This should be determined by your treatment plan.
How often will I need follow-up support tools?
Every three months for the first year, then every six months.
Which cancer cells do you test in an RGCC test?
In any tumour there are several subpopulations of cancer cells, but we only harvest and analyse cells with the tumour-initiating properties.